Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | POLE V464A |
Therapy | Nivolumab |
Indication/Tumor Type | colorectal cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
POLE V464A | colorectal cancer | predicted - sensitive | Nivolumab | Case Reports/Case Series | Actionable | In a Phase II trial, Opdivo (nivolumab) resulted in a durable complete response in a colorectal cancer patient harboring POLE V464A, along with high tumor mutational burden (PMID: 35398880; NCT03012581). | 35398880 |
PubMed Id | Reference Title | Details |
---|---|---|
(35398880) | PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. | Full reference... |